AI Drug Discovery on Korea Invest Insights

A Map of Biotech Investing: Where You Earn Only If the Drug Works, and Where You Earn Whichever Drug Works

Sat, 22 Aug 2026 14:20:00 +0900

Connecting context: Two days ago, a beginner’s map of eight US biotech trends drew the big picture of money moving from semiconductors into biotech and the Korean companies connected to it. Before that, May’s sector thesis argued that this is not a market for buying good technology but one for picking stocks the market has underpriced, and June’s six-stock check argued that a catalyst being alive and a stock being cheap are not the same thing. This piece redraws the eight-trend map along the axis of how revenue is earned and goes one level deeper, asking the same questions: where does the money get made, does it recur, and how much of that is already reflected in today’s price.

TL;DR

Sorting biotech by disease alone does not let you compare risk. You have to overlay four axes: disease, treatment modality, value chain, and economics, and the axis that divides risk is economics, meaning whether the payoff is a one-time milestone tied to a single trial or recurring revenue per patient.
Personalized oncology is a theme where therapeutics, diagnostics, recurrence monitoring, and data all fold into one pipeline. On August 19, Moderna and Merck’s Phase 3 trial of their individualized cancer vaccine met both of its endpoints, recurrence-free survival and distant metastasis-free survival, and Moderna’s stock jumped 177% in a single day. [Fact: company statements, market prices] However, a claim that circulates often in early drafts, that “1,137 patients had a customized therapeutic manufactured and delivered to them on schedule,” is wrong. The 1,137 patients are the total randomized on a 2-to-1 basis, actual dosing covered roughly 758 patients, and manufacturing success rates, hazard ratios, and overall survival have not been disclosed. [Fact: company statements]
The economics differ at every stage of the pipeline. Therapeutics pay off big if they succeed, but the trial outcome is binary. Recurrence monitoring tests generate recurring revenue that repeats many times per patient, and data is a high margin, long term contract business. This difference is what defines the investment structure.
Results on the recurring revenue axis back up the structure. Natera’s second-quarter revenue grew 37.7%, oncology testing grew 57.2%, and the company guided to positive cash flow in 2026. Guardant’s revenue grew 44%, but the company plans to burn roughly $200 million in cash this year. Tempus posted its first profitable quarter, but that quarter included a $98.5 million unrealized gain. [Fact: each company’s earnings release]
Saying the structure is good and saying it is cheap are two different claims. Natera and Guardant trade at 16x to 17x their 2026 revenue guidance, and Twist trades at around 20x, while BioNTech, Tempus, and Natera have risen 28%, 56%, and 63% respectively over the past three months. [Fact: arithmetic based on August 21 closing prices]
For validated treatment platforms, the problem is price. Enhertu posted first-half revenue of $2.96 billion, up 29%, and in radiopharmaceuticals, Curium agreed to acquire Lantheus for up to $8 billion. This is a zone where you need to pick by asset-level metrics rather than by platform name. [Fact: company statements]
The axis that most needs proof has, paradoxically, risen the most this year. No AI-discovered drug has been approved yet, but AbCellera is up 231% year to date, 10x Genomics is up 299%, and Twist is up 359%. [Fact: August 21 market prices] This is a place where price moved ahead of proof.
The conclusion for portfolio structure is a barbell. Hold companies that only earn if the drug works separately from companies that earn no matter which drug works, but at current prices, the leading names on each axis have all just rallied sharply, so entry-price discipline comes first.

Key Framing

Even within biotech, companies that make money in different ways are different assets. Therapeutics companies bet the company’s value on a single trial. Diagnostics and data companies benefit no matter which therapeutic succeeds: more patients means more tests, and more tests means more accumulated data. Personalized oncology is a rare theme where these two kinds of companies work on the same patients within the same pipeline, which is why the right approach is a barbell that judges and holds them separately. What is confirmed right now is that the Phase 3 trial ran to completion and the growth rates on the recurring revenue axis. What is not confirmed is the size of the therapeutic’s effect, the manufacturing success rate, and how much the market has already paid for this structure. The answer to that last question is 16x to 20x.

1. What Disease Classification Misses: Overlaying Four Axes

Classifying biotech as oncology, obesity, or rare disease only tells you what illness a drug targets. What investors need to know is what happens to the company if the drug fails, and what shape the revenue takes if it succeeds. So we add more axes.

Personalized oncology across four axes. Filled chips mark where this theme runs. Disease: oncology. Modality: individualized therapy. Value chain: patient selection through data. Economics: one-off milestones and recurring revenue per patient coexist in a single pipeline.

View as table

Axis	Components	Where personalized oncology runs
Disease	Oncology, immunology, metabolic, neurology, rare disease	Oncology
Modality	Antibody, ADC, bispecific, cell/gene/RNA, individualized	Individualized therapy
Value chain	Discovery, patient selection, treatment, manufacturing, monitoring, data	Patient selection through data
Economics	One-off clinical milestones, recurring revenue per patient	Both

Disease breaks down into oncology, immunology, metabolic disease, neurology, and rare disease. Treatment modality breaks down into antibodies, antibody-drug conjugates (ADCs), bispecifics, cell, gene, and RNA therapeutics, and individualized treatments made separately for each patient. The value chain runs from discovery through patient selection, treatment, manufacturing, outcome tracking, and data. Economics splits between a one-time milestone tied to a single trial outcome and recurring revenue that a single patient generates repeatedly.

Of these four axes, the one that divides risk is the last one. Two oncology companies can work on the same patients, and one can lose half its value on the day trial results come out while the other keeps earning test revenue for as long as that patient is being treated. Personalized oncology, the subject of this piece, is a theme where all four axes overlap in a single pipeline: the disease is oncology, the modality is individualized treatment, the value chain runs from selection to data, and the economics combine milestones with recurring revenue.

2. A Map of Fourteen Sub-Themes

The sub-themes are organized below by where value is created and by a current read on each. The representative names are illustrative examples for analysis.

Sub-theme	Where value is created	Representative names	Current read
Individualized cancer vaccines	Identifying patient-specific neoantigens and manufacturing a customized therapeutic	Moderna and Merck, BioNTech and Roche	The Phase 3 melanoma adjuvant trial met both endpoints on August 19. Effect size, manufacturing success rate, pricing, and expansion to other cancer types remain open
MRD and liquid biopsy	Repeat testing for pretreatment selection and post-treatment recurrence surveillance	Natera, Guardant, Tempus and Personalis	The best recurring revenue structure in the map. Test volume, reimbursement, and cash flow are the metrics to watch. Trades at 16x to 17x revenue, though
Precision medicine data platforms	Selling clinical, genomic, and outcomes data to pharmaceutical companies	Tempus	The moat strengthens as data accumulates. First profitable quarter included an unrealized gain; Personalis acquisition in progress
Companion diagnostics and biomarkers	Pre-selecting patients eligible for a specific drug	Natera, Guardant, Roche	A stable structure where drug approvals and test demand are tied together
ADC	Using antibodies to selectively deliver a toxic payload to cancer cells	AstraZeneca and Daiichi Sankyo, Gilead, BioNTech	Commercial validation complete. Enhertu posted $2.96 billion in first-half revenue. Target, linker, and payload differentiation, along with lung toxicity, separate the winners
Bispecifics and T-cell engagers	Directly binding immune cells to cancer cells	Amgen, Regeneron, Genmab, BioNTech	Efficacy is validated. Imdelltra posted second-quarter revenue of $288 million, up 115%. Cytokine release syndrome, dosing convenience, and manufacturing are the variables
Cell therapy 2.0	Extending CAR-T from blood cancers into autoimmune disease and solid tumors	Gilead, BMS, CRISPR Therapeutics, and others	Blood cancers are validated, autoimmune is pre-approval, and solid tumors have no US approval. Manufacturing time and cost are the bottleneck
Radiopharmaceuticals	Precisely delivering radioactive isotopes to cancer cells	Novartis, Eli Lilly, BMS, Curium and Lantheus	Pluvicto generated $1.994 billion in 2025, up 43%. Isotope supply and manufacturing capacity are the moat. Deal prices have reached as high as $8 billion
Gene editing	Making a one-time correction to the genetic cause of disease at the DNA level	CRISPR Therapeutics, Intellia, Beam	Ex vivo editing is validated by its first approval. 64 patients dosed in 2025, generating $116 million in revenue. In vivo delivery, safety, and one-time pricing are the open questions
RNA therapeutics	Suppressing gene expression or inducing protein production	Alnylam, Ionis, Arrowhead, Moderna	siRNA has an established commercial model (Alnylam posted $3.71 billion in 2025 revenue and turned profitable). But 2026 guidance was cut and the stock sold off sharply. mRNA therapeutics are awaiting rare-disease data
AI drug discovery	Accelerating target and molecule design and clinical patient selection	Recursion, Schrödinger, AbCellera, Tempus	No AI-discovered drug has been approved yet. Clinical entry, partner milestones, and royalties are the metrics
Synthetic biology and DNA manufacturing	Supplying the DNA and proteins that repeated experiments require	Twist	A tools supplier. Revenue grew 23%, with a target of breakeven adjusted EBITDA in the fourth quarter. Still trades at 20x revenue even after the equity offering
Next-generation sequencing and spatial omics	Measuring the tumor and immune microenvironment with greater precision	Illumina, 10x Genomics, PacBio	Essential infrastructure. Illumina has recovered since the China export ban was lifted, while PacBio cut guidance. Equipment cycles and price competition are the risks
Obesity and metabolic disease 2.0	Expanding into oral formulations, muscle-loss prevention, and combination therapy	Eli Lilly, Novo Nordisk	Two oral drugs have been approved. Goldman cut its 2030 market forecast from $130 billion to $95 billion. Clinical differentiation and pricing are the key questions

[Fact: company statements and news reports, as of August 21, 2026. Assessments are our own]

A map of fourteen themes. The x-axis is how far commercial validation has come; the y-axis is whether revenue is one-off or recurring. Coordinates are our own judgement and colors follow the priority groups in the text. The upper right is already expensive; the lower left has risen the most this year.

View as table

Theme	Validation	Revenue nature	Group
MRD, liquid biopsy	Proven	Recurring	Tier 1 recurring
Companion diagnostics	Proven	Recurring	Tier 1 recurring
Precision-medicine data	Intermediate	Recurring (long-term contracts)	Biggest option
Individualized cancer vaccines	Phase 3 met, pre-commercial	One course per patient	Biggest option
ADC	Proven	Repeated treatment cycles	Validated platforms
Bispecifics, T-cell engagers	Proven	Repeated treatment cycles	Validated platforms
Radiopharmaceuticals	Proven	Repeated treatment cycles	Validated platforms
Cell therapy 2.0	No solid-tumor or autoimmune approval	One-off	Needs proof
AI drug discovery	No approvals	Milestones, royalties	Needs proof
Synthetic biology, DNA	Intermediate	Repeat orders	Needs proof
Gene editing	Ex vivo only	One-off	Proven, stock-specific risk
RNA therapeutics	Proven	Chronic dosing	Proven, stock-specific risk
NGS, spatial omics	Proven	Instruments and consumables	Proven, stock-specific risk
Obesity 2.0	Proven	Chronic prescriptions	Proven, stock-specific risk

The map’s horizontal axis is how far commercial validation has progressed, and the vertical axis is whether revenue is one-time or recurring. The upper right is the best position and the lower left is the riskiest. The coordinates are our own judgment, not a precise measurement. But one thing reads true regardless of the coordinates: the upper right is already expensive, and the lower left has risen the most this year.

3. The Internal Structure of Personalized Oncology: Economics Differ at Every Stage

Personalized oncology is a circular structure that starts with one patient’s tumor and loops back into the treatment design for the next patient.

One pipeline, different economics. Green steps earn recurring revenue per patient, amber steps earn contract revenue from pharma and trials, and magenta steps earn therapeutic revenue that hangs on a single trial. The more the therapy succeeds, the more patients flow into the green steps.

View as table

Step	Content	Revenue nature
1	Tumor tissue and blood collection	One test
2	Genomic analysis, neoantigen selection	Pharma and trial contracts
3	Design and manufacture of the therapy	Therapeutic, binary trial
4	Combination with immunotherapy	Added to existing checkpoint-inhibitor sales
5	Repeated MRD measurement	Several times per patient
6	Outcome data accumulation	High-margin licences, long-term contracts
7	Selection and trial design for the next patient	Cumulative moat

Tumor tissue and blood are drawn from the patient and the genome is analyzed to select the neoantigens unique to that patient’s cancer. A therapeutic is designed and manufactured around those antigens and given in combination with an immuno-oncology drug. Once treatment ends, minimal residual disease (MRD) is measured repeatedly in the blood to monitor for recurrence, and those results accumulate as data that refines patient selection and trial design for the next patient.

Who makes money at each stage, and what shape that money takes, differs by stage.

Stage	Who benefits	Revenue characteristics	Most important metric
Therapeutic	Moderna and Merck, BioNTech	Large if successful, but the trial outcome is binary	Hazard ratio, overall survival, approval odds, price per patient
Analysis and design	Personalis (being acquired by Tempus), Tempus	Clinical trial and pharma contracts	Number of pharma customers, contracted backlog, analysis volume
Recurrence monitoring	Natera, Guardant, Personalis	Recurring revenue that occurs multiple times per patient	Test volume, average selling price per test, reimbursement, repeat frequency
Data	Tempus	High-margin licensing and long-term contracts	New bookings, data revenue growth, renewal rate
DNA manufacturing	Twist	Tied to R&D order volume	Order volume, gross margin, customer expansion

The therapeutic stage rides on a single Phase 3 trial. The recurrence monitoring stage repeats every quarter for as long as the patient is alive, and the more the therapeutic succeeds, the more patients there are to monitor. That the shape of risk can differ this much within a single theme is the starting point of this piece.

4. Results on the Recurring Revenue Axis: Good Structure, Expensive Price

Here are the second-quarter results for the recurring revenue axis.

Growth on the recurring-revenue axis. All four grew between the low 20s and mid 40s, but their cash-flow status differs. Green means positive cash flow or guided positive; amber means continued burn or a breakeven target. Q2 2026 (Twist: fiscal Q3 ended June).

View as table

Company	Latest-quarter revenue	Growth	Cash-flow status
Natera	$752.8m	+37.7%	2026 cash flow guided positive
Guardant	$335.0m	+44%	2026 free cash flow guided at -$195m to -$205m
Tempus	$382.5m	+22%	Adj. EBITDA +$8m; net income includes a $98.5m valuation gain
Twist	$118.4m	+23.2%	Q4 adj. EBITDA breakeven targeted

Natera’s second-quarter revenue was $752.8 million, up 37.7%, and oncology testing volume was 296,700 tests, up 57.2%. Quarterly test volume topped one million for the second straight quarter, and gross margin was 64.5%. Signatera’s average selling price per test is about $1,275, and the company has set a long-term target of around $2,000. It raised its full-year revenue guidance to a range of $2.85 billion to $2.91 billion and said it expects positive cash flow in 2026. [Fact: company statements] There is no specific dollar guidance for that figure.

Guardant’s second-quarter revenue was $335 million, up 44%. Oncology testing revenue grew 38%, and Shield, its colorectal cancer screening test, generated $52.9 million, 3.6 times what it generated a year earlier. But quarterly free cash flow was an outflow of $69.5 million, and the company guided to a 2026 free cash flow outflow of $195 million to $205 million, actually widening the range of the outflow. [Fact: company statements] In effect, the revenue guidance and the cash outflow guidance both went up together.

Tempus’s second-quarter revenue was $382.5 million, up 22%, and adjusted EBITDA was a positive $8 million. Its GAAP net income of $5.6 million marked the company’s first profitable quarter, but that figure includes a $98.5 million unrealized gain on securities, offset in part by $55.6 million in stock-based compensation. [Fact: company statements] In other words, the profit came from an unrealized gain rather than from operations. Full-year revenue guidance is $1.595 billion to $1.605 billion, with adjusted EBITDA of around $65 million. On July 20, Tempus agreed to acquire Personalis for $16.25 per share, an enterprise value of roughly $1.5 billion net of Personalis’s existing stake, with the deal expected to close late this year or early next year. [Fact: company statements] Tempus’s own MRD test, xM, runs about 9,000 tests per quarter.

Twist’s fiscal third-quarter revenue was $118.38 million, up 23.2%, with a gross margin of 52.8%. The company guided to 21% full-year growth and breakeven adjusted EBITDA in the fourth quarter. On August 4 it raised $300 million in an equity offering at $96 per share, and its August 21 closing price was $145.59. [Fact: company statements, market prices] That is 52% above the offering price in just two weeks.

Now look at the price the market has paid for these results.

The price paid for the structure. Market cap divided by the midpoint of 2026 revenue guidance, a simple multiple with net cash not deducted. Twist uses the midpoint of two market-cap tallies ($9.1bn and $9.6bn). Below each bar is the three-month share-price move to August 21.

View as table

Company	Market cap (Aug 21)	2026 revenue guidance	Multiple	3-month move
Natera	$47.86bn	$2.85bn to $2.91bn	16.6x	+63%
Guardant	$22.91bn	$1.34bn to $1.36bn	17.0x	+45%
Tempus	$13.12bn	$1.595bn to $1.605bn	8.2x	+56%
Twist	$9.1bn to $9.6bn	$456m to $457m (fiscal year)	20x to 21x	+147%

Dividing market cap by the midpoint of each company’s 2026 revenue guidance gives 16.6x for Natera, 17.0x for Guardant, 8.2x for Tempus, and around 20x for Twist. This is a simple revenue multiple that does not net out cash. [Fact: our own arithmetic based on August 21 closing prices] Tempus looks cheapest because its revenue is large relative to its market cap, not because the market has bid it up less. Tempus is up 56% over the past three months.

The recurring revenue structure has weaknesses too. Test revenue is set by reimbursement, and any increase in price per test has to be preceded by broader coverage. Competition is heavy as well. Beyond Natera, Guardant, Tempus, and Personalis, Exact Sciences and Roche’s Foundation Medicine compete for the same patients. And as Guardant shows, revenue can grow 44% while cash keeps going out the door. Judging the structure to be good and judging 16x to 17x to be cheap are two separate calls.

5. The Therapeutics Axis: What the Phase 3 Trial Proved, and What It Has Not

On August 19, Merck and Moderna announced that the Phase 3 trial (INTerpath-001) of their individualized neoantigen therapeutic intismeran autogene in combination with Keytruda met both of its endpoints, recurrence-free survival and distant metastasis-free survival, in patients with resected melanoma. The trial enrolled 1,137 patients, randomized 2 to 1 between the combination arm and the control arm. Moderna’s stock rose 176.97% that day to close at $174.38, then fell 19.8% the next day, while Merck rose by around 11%. [Fact: company statements, market prices]

Here is precisely what the Phase 3 trial proved. A different therapeutic was manufactured for each patient, and a trial of Phase 3 scale was carried through to completion, with the direction of effect matching Phase 2. In the five-year follow-up of the Phase 2 trial KEYNOTE-942, the hazard ratio for recurrence was 0.51 (confidence interval 0.29 to 0.89), and the hazard ratio for distant metastasis was 0.41. [Fact: ASCO 2026, JCO] The Phase 3 hazard ratio will not be disclosed until it is presented at a medical conference.

Here is what it did not prove. With a 2-to-1 allocation, only about 758 patients actually received intismeran. The claim that all 1,137 patients received a customized therapeutic is wrong, and neither company has ever disclosed the share of patient-specific manufacturing runs completed on schedule, in other words the manufacturing success rate. [Fact: review of company statements] Absolute efficacy by disease stage, overall survival, price per patient, and reimbursement are all still undisclosed. Moderna’s personalized therapeutics plant in Marlborough, built for more than $322 million, began supplying clinical trial material in September 2025, and the company says approval could come as early as 2027. [Fact: company materials] Work in other cancer types is underway but uneven. Two Phase 3 trials are ongoing in non-small cell lung cancer, while the cutaneous squamous cell carcinoma program was discontinued after Keytruda failed on its own in that indication. [Fact: trial registries, news reports]

The same Phase 3 success means something different to each company. Moderna’s second-quarter revenue was $145 million, its net loss was $782 million, and it holds $6.9 billion in cash while cutting annual cash costs to around $4 billion. [Fact: company statements] If approval comes in 2027, the point at which the Phase 3 success changes the P&L is later still. For Merck, Keytruda’s core composition-of-matter patent expires in December 2028, with more than $25 billion in annual revenue riding on it. [Fact: news reports] A successful combination therapeutic is a way to push that cliff back. The reason Merck’s stock moved is that this Phase 3 trial became the first answer to the question of what Keytruda’s revenue looks like after 2028.

BioNTech is the name with the thickest downside cushion on this axis. At the end of June, its cash and securities stood at €16.63 billion, more than half its $29.3 billion market cap. [Fact: company statements, August 21 market cap] Its late-stage pipeline includes BNT327, the PD-L1/VEGF bispecific it shares with BMS, which is running seven pivotal trials, and gotistobart’s overall survival hazard ratio, reported in March, was 0.46. There are caveats, though. 2026 revenue guidance was cut to a range of €1.6 billion to €1.9 billion, and the US approval filing for the HER2 ADC BNT323 has not yet been submitted, though it is under review in China. Autogene cevumeran, the individualized cancer vaccine it is developing with Roche, has an ongoing Phase 2 trial in pancreatic cancer, but colorectal cancer results have slipped to 2027 and the urothelial cancer program was discontinued. [Fact: company statements, news reports] The case for good asymmetry rests on the cash cushioning the downside and the multiple late-stage trials, not on having an already-approved oncology drug.

6. The Price Problem for Validated Platforms: ADCs, Bispecifics, and Radiopharmaceuticals

On this axis, the odds of clinical success and the path to commercialization are relatively clear. Enhertu’s first-half revenue was $2.96 billion, up 29%, and Datroway and Trodelvy were approved in May and June respectively for first-line triple-negative breast cancer. Trodelvy’s first-half revenue was $859 million, up 31%. Among bispecifics, Amgen’s Imdelltra generated $288 million in the second quarter, up 115%, and in a second-line small cell lung cancer Phase 3 trial it showed median overall survival of 13.6 months versus 8.3 months, a hazard ratio of 0.60. Genmab’s Epkinly generated $312 million in the first half, up 48%. In radiopharmaceuticals, Novartis’s Pluvicto generated $1.994 billion in 2025, up 43%, and on July 31 its label was expanded to metastatic hormone-sensitive prostate cancer. [Fact: company statements]

Being validated also means being priced in. From the start of 2026 through August 18, there were 69 biopharma acquisitions with disclosed values totaling $189.1 billion, and on August 3, Curium agreed to acquire Lantheus for up to $8 billion including contingent consideration. That is a step up from earlier radiopharmaceutical deals: BMS’s $4.1 billion acquisition of RayzeBio, AstraZeneca’s $2.4 billion acquisition of Fusion, and Eli Lilly’s $1.4 billion acquisition of Point Biopharma. [Fact: deal tracking, company statements] Large companies buy the best assets first. Picking among what is left requires looking at asset-level metrics rather than platform names, and by 2026 each of those metrics had a real-world example attached to it.

Metric to check	Recent real-world example
Response rate and survival benefit versus existing treatment	Imdelltra’s Phase 3 overall survival of 13.6 months versus 8.3 months
Toxicity and discontinuation rate	Daiichi Sankyo and Merck’s B7-H3 ADC, placed under a partial clinical hold after fatal lung toxicity
Range of treatable patients	Datroway and Trodelvy’s expansion into first-line triple-negative breast cancer
Launch spacing between competing drugs	Summit and Akeso’s ivonescimab has a PDUFA date of November 14; BNT327 has seven pivotal trials underway
Manufacturing capacity and supply bottlenecks	A second complete response letter for Regeneron’s odronextamab over manufacturing facility issues, and a Phase 3 trial halted due to an actinium-225 shortage

[Fact: company statements, FDA, news reports]

The last row captures what defines this axis. A bispecific can be a good drug and still get stuck on a facility inspection, and a radiopharmaceutical trial stops if the isotope supply runs out. That is why Novartis is building an isotope production facility in Indianapolis and adding a third manufacturing site in California. [Fact: company statements] On this axis, the moat sits in the supply chain, not in the molecule.

7. The Axis That Still Needs Proof, Yet Has Risen the Most

AI drug discovery, synthetic biology, solid-tumor cell therapy, and parts of gene editing and RNA are technologically interesting, but the revenue moat has not been proven.

Start with AI drug discovery. As of August 22, no drug has been approved that is credited to an AI platform’s discovery. [Fact: review of regulatory records] According to one published tally, of 117 AI-derived drug candidates, 51.3% completed Phase 1 and 6.8% completed Phase 2, while another tally puts the Phase 1 success rate at 80% to 90%, falling to around 40% in Phase 2. [Fact: conference and consulting tallies, data from 2023 to 2025] If Phase 1 passes easily but candidates stall in Phase 2, the problem lies not in molecule design but in target selection and disease understanding. [Inference: reading of the tallies]

Corporate results point the same way. Recursion’s second-quarter revenue was $7.67 million, below expectations, with a net loss of $131 million and cash of $556.8 million, enough to last into early 2028. Schrödinger’s software revenue was $200 million in 2025, up 11%, and AbCellera received $84 million in upfront payments from Jazz and Vertex in the second quarter. Alphabet’s Isomorphic Labs raised $2.1 billion in May, but as of the start of the year it was still only at the stage of saying its target was to dose its first patient sometime within the year. [Fact: company statements, news reports] The conclusion that what matters is clinical entry, cash milestones, and repeat customer revenue, not technology announcements and partnership headline numbers, comes from this evidence.

Solid-tumor cell therapy has no US approval. The world’s first solid-tumor CAR-T approval went to China’s CARsgen on June 22, and autoimmune CAR-T maker Kyverna is targeting a completed approval filing in the fourth quarter of this year. The existing blood-cancer CAR-T business is stagnant. Gilead’s cell therapy revenue was $417 million in the second quarter, down 14%. Instead, acquisitions have piled into in vivo CAR-T technology since 2025: AbbVie for up to $2.1 billion, BMS for about $1.5 billion, and AstraZeneca for up to $1 billion. [Fact: company statements, news reports] This is an attempt to solve the manufacturing time and cost bottleneck inside the patient’s body rather than in a factory, and it is still at the stage of first clinical data.

In gene editing, only ex vivo editing is validated. Casgevy had 301 patients start treatment in 2025, of whom 64 were dosed, generating $116 million in revenue at a list price of $2.2 million. In vivo editing saw Intellia’s clinical hold, imposed after a patient death in November 2025, lifted in January and March of this year, and in February the FDA issued draft guidance on a new approval pathway for patient-customized editing therapies. [Fact: company statements, FDA] In RNA, siRNA has built a commercial model, yet its leading company’s stock is down 40.6% this year. Alnylam turned profitable in 2025, with revenue of $3.71 billion and net income of $313.7 million, but cut its 2026 guidance on July 30. [Fact: company statements, market prices] This is a case where having an established commercial model and having a strong stock are two different things.

Yet looking at stock prices on this axis, proof and price are in reverse order. As of August 21, year-to-date gains stand at 359% for Twist, 299% for 10x Genomics, 231% for AbCellera, and 67% for Illumina. [Fact: market prices] Tools and infrastructure companies have risen far more than biotech as a whole (the XBI is up 35.9%). Illumina’s second-quarter revenue grew 9.5% after China’s export ban was lifted in November 2025, prompting it to raise full-year guidance, and 10x Genomics saw its spatial analysis consumables grow 16%. The recovery is real. But PacBio’s second-quarter revenue was flat, leading it to cut full-year guidance and push its breakeven target out to 2028. [Fact: company statements] Within the same axis, the recovery is uneven, yet price moved first. This is the place where entry-price discipline applies most mechanically.

8. Overall Priority Ranking and the Barbell

Here is a ranking of investment structures across biotech today. The ranking reflects structural quality, not a signal to buy now.

Rank	Theme	Basis for the structure	Caveat as of August 2026
1	MRD and companion diagnostics	Recurring revenue and clinical necessity. Testing grows regardless of which therapeutic succeeds	Trades at 16x to 17x revenue. Guardant continues to burn cash
2	Precision medicine data	The moat strengthens as test data accumulates	First profitable quarter included an unrealized gain. Acquisition set to close early next year
3	Individualized cancer vaccines	The largest clinical and value optionality	Phase 3 succeeded. Effect size, manufacturing success rate, and pricing undisclosed
4	ADCs and radiopharmaceuticals	Treatment platforms with validated commercialization	Deal prices up to $8 billion. Selection requires asset-level metrics
5	RNA and gene editing	Technology is validated, but stock-by-stock outcomes remain binary	Leading company cut guidance. In vivo editing is still at the safety stage
6	AI drug discovery and synthetic biology	An early-stage theme that still needs to prove revenue conversion	No approvals yet. Stocks are up three to four times year to date

From an equity standpoint, the conclusion is a barbell. Judge and hold separately the companies with the greatest odds of therapeutic success and the companies that make money no matter which therapeutic succeeds. Treatment optionality names like BioNTech and Moderna and diagnostics and data recurring-revenue names like Natera and Tempus sit within the same theme but are different assets. The value of the former is decided on the day trial results come out, while the value of the latter builds up through patient counts and reimbursement. Buying both under a single “personalized oncology” basket means buying without understanding the shape of the risk.

At current prices, the leading name on each axis shows something different. What BioNTech shows is asymmetry backed by cash worth more than half its market cap. Tempus shows a business position that connects diagnostics, data, and MRD within a single company, while Natera shows fundamental quality, with test volume, margin, and cash flow all improving together. And all three stocks have risen 28%, 56%, and 63% respectively over the past three months, with those gains concentrated around August’s earnings and the Phase 3 announcement. [Fact: August 21 market prices] The XBI is up 35.9% year to date and sits 2.3% below its 52-week high. At the end of July it was up 20.7% year to date, so more than half of that gain came in the past three weeks alone. [Fact: fund manager data, market prices] The ranking by structure and the ranking by entry point are different things. Right now, the latter beats the former.

Laying the same map over Korean biotech reveals the connection. Among the names this blog has covered, LigaChem Biosciences sits on the ADC axis, Alteogen sits on the recurring revenue axis through subcutaneous-conversion royalties, Lunit sits on the AI-based biomarker axis, and Samsung Biologics and ST Pharm sit on the manufacturing axis that gets volume regardless of which drug succeeds. June’s verdict was that the good companies among them were already in expensive territory. That matches the conclusion from the US map. The market recognizes first which positions earn money no matter which drug succeeds, and investors arrive only after the price in that position has already priced in most of the structural advantage.

The names mentioned in this piece are illustrative examples for analysis and do not constitute a recommendation to buy or sell any specific stock. Responsibility for investment decisions and their outcomes rests with the investor. Prices and market capitalizations are as of US market close on August 21, 2026, and revenue multiples are market cap divided by the midpoint of each company’s 2026 revenue guidance (fiscal year 2026 for Twist), without netting out cash. The coordinates on the theme map reflect our own judgment. The Phase 3 trial’s hazard ratio, overall survival, and manufacturing success rate have not been disclosed by the companies, and the contribution of the Phase 3 announcement to BioNTech’s share price gain cannot be isolated. Certain items, including Alnylam’s second-quarter revenue by product and the most recent year in the AI candidate tally, relied on secondary sources.

What's Happening in US Biotech? A Beginner's Map of 8 Big Trends and Their Korean Connections (2026-08-20)

Thu, 20 Aug 2026 10:30:00 +0900

🔗 Read together: Six Korean bio stocks, made simple: ’the catalyst is alive’ and ‘it’s cheap’ are not the same thing · Our Korea bio-sector thesis: the market that rewards under-priced data · The Real Money flow framework

In June we sorted six Korean bio names by “catalyst vs price.” This post lifts the lens one level up: what is actually happening in US biotech, and which Korean companies does that wave reach? It cross-checks 108 public sources against a full quantitative screen of Korean listed biotechs, written for beginners, with every piece of jargon unpacked and visuals throughout. It is long, but it is designed so that one read gives you the whole US biotech picture.

TL;DR (3 lines)

US biotech is up +88.8% in a year and has become a leading sector; over the past month, money has been rotating out of semiconductors into biotech. Three engines: an M&A supercycle, rate-cut hopes, and a reopened IPO window.
Two game-changing events landed on August 18 and 19. The first-ever Phase 3 success for an mRNA cancer therapy (Merck and Moderna), and lab-validated protein design by an AI (Claude, verified via Twist). The theme count went from 7 to 8.
Fewer Korean companies than you might think are connected to this wave by actual contracts. Some have both substance and momentum (Alteogen, HanAll), some have strong substance but depressed prices (LigaChem, ABL Bio), and some merely borrowed the theme. Telling those three apart is the point of this post.

Before we start: the 6 words this post keeps using

Know these and the rest reads easily.

Term	Plain meaning
XBI	An ETF holding US small/mid-cap biotechs. Think of it as the thermometer of US biotech.
Licensing-out (L/O)	Selling your drug candidate to a global pharma: an upfront payment, milestones (paid on success), and royalties.
Royalty	A percentage of sales you keep receiving every time the exported drug sells. The highest-quality income in biotech.
CDMO	A factory that makes other people’s drugs. Whether the drug succeeds or not, orders mean revenue.
Binary event	An event whose outcome is one of two (trial readout, approval decision). The stock can move tens of percent in a day.
Patent cliff	When a blockbuster’s patent expires and revenue falls off a cliff. This fear is the root engine behind biotech M&A.

Key sentence

The US biotech rally runs on structural money flows: big pharma's acquisition needs driven by the patent cliff, rate cuts, and a reopened IPO window. So the Korean investor's question should not be "US biotech is up, let's buy Korean bio," but "which Korean companies are connected to that wave by actual contracts?"

1. The big picture: money is moving from semis to biotech

Numbers first. XBI, the US biotech thermometer, is up +88.8% over the past year and +39.1% year-to-date. Isolate the last month and you get biotech +9.7% vs semiconductors −6.0%. While the chip trade that led all year takes a break, funds are rotating into biotech, and the rotation is now measurable.

One thing beginners often misread. A +88.8% print also carries a warning: much is already priced in. Anyone entering now is betting on year two of a rally, which is why this post keeps asking what is still under-priced.

2. The rally’s three engines: why biotech, why now

This rally runs on three structural engines.

The patent cliff: the real reason behind the M&A supercycle

The strongest of the three engines is M&A, and its root is the patent cliff. Keytruda (Merck), the world’s best-selling cancer drug, loses patent protection in 2028. Once a patent expires, copies flood in and revenue drops like a cliff. Big pharma revenue exposed this way through 2030 is estimated at $170B–300B.

Why this matters for Korean investors comes down to one line. In an era when big pharma must fill pipelines with money, demand for Korean biotechs’ licensing deals grows too.

3. Two days in August that changed the map

Two events between August 18 and 19 forced the theme map to be redrawn.

Event ① The first-ever Phase 3 win for an mRNA cancer therapy (8/19)

Merck and Moderna’s personalized cancer vaccine, intismeran autogene (mRNA-4157), combined with Keytruda in a Phase 3 trial of 1,137 resected stage IIB–IV melanoma patients, significantly reduced both recurrence risk (RFS, the primary endpoint) and distant-metastasis risk (DMFS, the key secondary endpoint). Across personalized neoantigen therapy and mRNA-based cancer treatment, this is the first Phase 3 success in history.

To be precise up front: this is a Phase 3 success, and approval has not been granted yet. The companies are beginning approval discussions with regulators, and the effect size (how much better, in absolute terms) stays undisclosed until the full data are presented at a conference.

It is still a big deal, because the way this drug works creates a new kind of industrial demand.

Three investment implications. ① A re-rating of Moderna itself (its pipeline option value revives), ② Merck’s acquisition appetite grows stronger because it must fill the Keytruda patent cliff (2028), ③ personalized therapy requires per-patient manufacturing, so approval would structurally lift mRNA manufacturing (CDMO) demand. That third point leads to the Korean link we cover later (ST Pharm).

Event ② An AI designed proteins, and outside labs verified it (8/18)

Anthropic announced that its AI model Claude designed de novo binder proteins for 14 of 15 targets. The lab numbers matter most here. The hit rate (the share of designed proteins that actually bound their targets) was 22~35%, roughly double the industry norm of 10~15%, and the verification was performed independently by two outside companies, Twist Bioscience and Adaptyv Bio, rather than by Anthropic itself. Twist put it in an 8-K filing and its stock jumped +17% in a day (its biggest move since 2021).

What makes this interesting is what it suggests about where the money is made in the “AI drug discovery” theme. Until now the stars were listed “AI biotechs” (e.g., Recursion). But the capability was demonstrated by an unlisted frontier AI lab, and the listed company that actually made money was the infrastructure firm that synthesizes and verifies the designs (Twist). In a gold rush, the shop selling picks and shovels earns the surest money.

A sober counterpoint belongs right next to this. Binding is not the same as being a drug (binding ≠ efficacy ≠ safety ≠ clinical success). Skeptics spoke up immediately. Until clinical value is proven, the only verifiable cash flow in this theme is tool-layer revenue (companies like Twist). And a formal commercial contract between Twist and Anthropic has not been confirmed. What exists today is verification work plus expectations.

Conflict-of-interest note: posts on this blog are written with the help of Anthropic’s AI model (Claude). In other words, the model of the company involved in the event above is writing this text. That is why this item is presented strictly alongside external verification (Twist’s 8-K, two independent labs) and skepticism, and readers should weigh this conflict when judging it.

4. The 8 US themes at a glance

With the two events included, US biotech’s leading themes settle into eight.

Theme ① Next-gen obesity
The race for "what comes after Wegovy": pills instead of injections, muscle preservation. Lilly's oral drug won FDA approval in April. Anchors: Lilly, Novo, Pfizer / small-cap VKTX

Theme ② China licensing & geopolitics
Big pharma is licensing Chinese biotech assets at scale ($137.7B in 2025, up 10x), while US legislation targeting Chinese bio firms (BIOSECURE, effective 12/18) cuts across it. Anchor: Pfizer / small-cap SMMT

Theme ③ M&A supercycle & patent cliff
$123B+ in H1, already past full-year 2025. All of US small/mid biotech trades as a "takeover call option." Anchors: Lilly, Gilead, GSK, AbbVie

Theme ④ Radioligand therapy (RLT)
'Guided-missile' therapy delivering radioactive payloads only to cancer cells. Curium–Lantheus $8.0B deal (sector record). This year's first biotech IPO was here too (Aktis, $318M). Anchor: Novartis / small-cap AKTS

Theme ⑤ CNS (brain & neuropsychiatry)
Huge unmet need (Alzheimer's psychosis etc.), but the highest clinical failure rate of any field. BMS's big readout (ADEPT) due in H2. Anchors: BMS, Lilly

Theme ⑥ Autoimmune cell therapy
Applying CAR-T (a cancer cell therapy) to autoimmune diseases like lupus. Validated by AbbVie and Gilead acquisitions. Anchors: AbbVie, Gilead / small-caps CABA, KYTX

Theme ⑦ AI drug discovery (redefined 8/18)
Value migrating from 'AI biotechs' to frontier AI labs (unlisted) plus verification/synthesis infrastructure (picks and shovels). Names: TWST (infrastructure), SDGR. No pure anchor

Theme ⑧ The mRNA renaissance (new, 8/19)
A cancer Phase 3 win plus a flu-vaccine approval: double re-validation in two weeks. Personalized manufacturing → CDMO demand. Anchors: Merck, Moderna / BNTX, the mRNA CDMO chain

ADCs (drugs made by attaching payloads to antibodies) are absorbed into ② (licensing) and ③ (M&A) as their main modality rather than standing alone. Korea’s LigaChem Bio plugs in exactly there.

One step deeper into each theme

① Next-gen obesity: the “next round” of the market Wegovy and Zepbound opened. The competitive axis is moving from injections to pills (oral) and to the quality of weight loss (muscle preservation). Lilly’s oral orforglipron won FDA approval in April, and the third-generation candidate retatrutide showed −28.3% weight loss in Phase 3. Pfizer’s $10B purchase of amylin player Metsera reset the price tag on “next-gen mechanisms.” Watch out: next-gen candidates have already failed to beat incumbents in some trials, and drug-price pressure is heavy.

② China licensing and geopolitics: big pharma’s licensing of Chinese candidates hit $137.7B in 2025, ten times the prior year. On the other side, the US completed legislation restricting business with Chinese bio firms (BIOSECURE), and the restricted-entity list takes effect December 18. The emblematic stock at this crossroads is SMMT (a PD-1×VEGF bispecific licensed from China’s Akeso), carrying a date-stamped event: the FDA decision (PDUFA) on November 14.

③ M&A supercycle: the patent-cliff chart above says it all. Companies with late-stage assets plus breakthrough designations keep getting bought.

④ Radioligand therapy (RLT): molecules that home in on markers on cancer cells, carrying radioactive isotopes. Literally guided-missile oncology. Novartis’s Pluvicto proved the commercial case, and the Curium–Lantheus $8.0B deal in early August reset sector valuations. Watch out: isotope supply bottlenecks (Ac-225) and a precedent of failing to prove survival benefit.

⑤ CNS: the biggest event is the H2 readout of ADEPT, which extends BMS’s schizophrenia drug Cobenfy into Alzheimer’s-disease psychosis. But CNS carries the highest failure base rate of any disease area, so indirect exposure through large caps like BMS beats a single-readout small cap here.

⑥ Autoimmune cell therapy: taking CAR-T (re-engineering a patient’s own immune cells) from blood cancer into autoimmune diseases like lupus. NEJM published in-vivo data (re-engineering cells inside the body), and acquisitions by AbbVie and Gilead validated the theme. It neighbors the autoimmune (FcRn) axis where Korea’s HanAll Biopharma connects.

⑦ and ⑧ are the two events described in section 3.

5. US names to watch: priorities, and the discipline behind them

Ranking the high-risk small/mid-cap (“high-beta”) names on four criteria gives this order. For beginners, the criteria matter more than the tickers: ⓐ clarity and proximity of the event, ⓑ risk-reward (drawdown, cash), ⓒ theme tailwind, ⓓ how much is already priced in.

Rank	Ticker	Theme	Why this rank (plain version)	Key event
1	SMMT	② geopolitics	Price down −56% from highs + a date-stamped event (FDA decision 11/14) + improved survival data	PDUFA 11/14
2	VKTX	① obesity	Phase 3 enrollment complete + $502M cash + $4.2B market cap. Against Pfizer’s $10B deal, it reads as a takeover candidate	Multiple Q3 readouts
3	AKTS	④ RLT	The $8B deal reset valuations + $538M cash. But its own data are far out (early 2027)	Trial start
4	CABA/KYTX	⑥ autoimmune	Low-cap survivors of an M&A-validated theme	Conference data, approval track
5	GPCR	① oral obesity	Journal publication + Phase 3 entry. Ranked lower because data are far away	Ph3 start

What about the two headliners of 8/18~19, MRNA and TWST? This is where the discipline bites. “They are anchors that validated the themes, but not chase-buys right after a gap-up.” The good news entered the price via the gap, so they are excluded from first-priority new additions; the discipline is to wait for pullbacks and full data. The principle “stand before the event, do not chase after it” applies to Korean names just the same.

One more piece of discipline. High-risk names like these get a single-digit percent of the portfolio as a total cap, one third of that per name at most, spread across different themes, and never a full bet before a readout (enter in tranches). These rules came out of a post-mortem on July’s drawdown.

6. The Korea linkage map: where does this wave land?

Now the main course. Here is the map of where the 8 US themes connect to Korean listed companies through actual contracts.

Company by company: what is substance and what is hope

This post scores each name on substance (filings and contracts) crossed with quant (price relative strength, RS, and institutional/foreign flows). The RS percentile answers “among all Korean stocks, what percentile is this stock’s recent price momentum?” on a 0~100 scale (93 means top 7%).

Alteogen: the only one already collecting royalties from an FDA-approved product. Covered here many times. Keytruda SC, built on its IV-to-subcutaneous platform (ALT-B4), won FDA approval, and royalties have started flowing into actual revenue (Q2 revenue +262%). An Enhertu SC upfront of $20M and a KOSPI transfer are also in motion. Because the cash flow rests on an approved product rather than on promises, it ranks highest on substance among the Korean links. RS 47 (middle), flows +₩7.5bn.

HanAll Biopharma: the partner’s clinical success is already in the numbers. It licensed an FcRn-mechanism drug (removing the antibodies that cause autoimmune disease) to US-based Immunovant, whose candidate IMVT-1402 posted a strong ACR20 of 72.7% (share of patients with 20%+ symptom improvement) in a rheumatoid-arthritis Phase 2b. Serial indication-by-indication readouts come in H2. At RS 93 (top 7%), it is the rare case where substance and momentum are high at the same time. One caveat: recent flows show profit-taking at −₩5.1bn.

Samsung Biologics: classified as the anchor. A beneficiary of the BIOSECURE act (effective 12/18) restricting Chinese CDMOs, plus the completed GSK Rockville plant purchase and a ₩6.8tn order backlog. Our June post filed it under “great company, already expensive,” but in this phase it is the main body of the rotation trade (institutions+foreigners +₩365bn over 20 days). Sector exposure rather than a high-risk bet.

OliX: the siRNA company with a real Lilly contract. It licensed its obesity/MASH candidate (OLX702A) to Lilly for a total of ₩911.7bn, and Lilly took over Phase 1 directly. One of the few Korean names tied to theme ① by an actual contract. RS 92 puts momentum high too; the −₩18.9bn outflow is the watch item.

LigaChem Bio: a candidate for Korea’s biggest bio catalyst this year. It licensed an ADC to J&J for $1.7B, and whether J&J exercises its Phase 2 co-development option (≈$200M) is the biggest ‘26 event (not yet exercised). Exercise would mean the world’s largest pharma re-validating the technology. The price sits at RS 23, deep in drawdown. A textbook case of strong substance with a depressed price.

ABL Bio: a brain-delivery platform contracted with two big pharmas. Its BBB-shuttle technology (getting drugs across the blood-brain barrier) is licensed to GSK for about ₩4tn total (upfront ₩73.9bn) and to Lilly for $2.6B total (₩80.5bn already received). The price sits at RS 33, the largest drawdown relative to substance.

ST Pharm: Korea’s closest exposure to theme ⑧ (mRNA). On top of the oligo CDMO earnings covered in June (a $56M supply deal for a commercial US drug, among consecutive wins), it holds mRNA CDMO capability (its own capping technology). If personalized mRNA cancer vaccines are approved, per-patient manufacturing demand grows structurally, and ST Pharm is the closest Korean listed company to that value chain. To be honest about it: no direct intismeran-related order has been confirmed. The capability is fact; the orders are still hope.

Hanmi Pharm: waiting on data. Dosing has finished in the Phase 2b of the MASH candidate (efpegdutide) licensed to MSD, with analysis under way. Note that its ₩1.9tn Lilly deal is a short-bowel-syndrome (GLP-2) drug, not an obesity drug. The market often mislabels it as an obesity story, so keep the two apart.

FutureChem: an ultra-high-risk double binary. Dosing is complete in the US Phase 2a of its prostate-cancer radioligand (FC705) with H2 results pending, and licensing talks remain unsigned. Both the data and the deal have to work, so it is sized as an option (small). RS 4 (bottom decile).

Orum Therapeutics: platform substance, small size. Its DAC technology (attaching protein degraders to antibodies) is licensed to BMS ($100M upfront) with a Vertex option. But Q1 revenue was zero, so milestone timing is the risk.

One chart: the substance × momentum quadrant

Final priorities (research priorities, not investment advice):

Group A (core candidates): Alteogen, HanAll Biopharma. Substance and quant both rank high
Group B (accumulation-in-drawdown): LigaChem Bio, ABL Bio, ST Pharm. Contract substance is solid and catalysts are clear, but tranches (staged entry) are the premise
Group C (event options, small size): OliX, Orum Therapeutics, FutureChem. Acknowledge the binary nature and size them as options
Anchor: Samsung Biologics (plus Celltrion). The main body of the rotation trade

One important footnote on flows. Over 20 days, institutions appeared to accumulate LigaChem (+₩21.2bn) and ABL Bio (+₩23.6bn), but over the latest 7 sessions institutions were net sellers and foreigners net buyers. “Institutions are buying” always depends on the window. And above all, observed accumulation never guarantees a bottom.

7. The caution list: names that borrowed the theme without the substance

The most dangerous thing for a beginner is a stock whose theme link is exaggerated relative to its substance. Here is what verification turned up:

Name	The story going around	Verified reality
Peptron	“A deal with Lilly”	A pre-contract evaluation agreement (running to Oct ‘26). Reports say competitor Camurus exercised its option; flows −₩38.6bn
D&D Pharmatech	“Pfizer partner”	Pfizer discontinued the relevant candidate (MET-224o). The risk event is live
Binex	“BIOSECURE beneficiary”	Only ‘hopes’ of benefit. No major order filing
Syntekabio	“AI drug discovery”	Revenue of ₩3.4bn against the theme talk
DuChemBio	“Therapeutic radio-CDMO”	A ‘plan’ stage targeting 2030
Inventage Lab	“Boehringer deal”	An undisclosed-amount joint research arrangement

See the common pattern? “Global pharma name + unclear contract type.” A definitive license (with total value and milestones in a filing) and an evaluation agreement or joint research differ like night and day, yet headlines render both as “XX joins hands with global big pharma.” Check first whether the type and amount of the contract are confirmed in filings.

8. The Q4 event calendar and the risks

A defining feature of this cycle: the binary events cluster in Q4.

The honest risk list (red team)

Entering year two of a rally: buying after a +88.8% year is itself a risk. If inflation reignites and the rate path flips, biotech, with only future profits, gets hit first.
Binary clustering: SMMT on 11/14, CagriSema in Q4, and BIOSECURE on 12/18 are stacked in one quarter; outcomes can swing the whole sector both ways.
Limits of the two August events: the cancer vaccine’s absolute effect size is undisclosed (a small number would mean a pullback), and personalized manufacturing still faces cost and reimbursement hurdles. Claude’s protein design sits far from clinical value, and Twist’s spike could fade as a one-off.
Misreading Korean flows: “institutional accumulation equals a bottom” is not a valid equation. Institutions were net sellers of LigaChem and ABL Bio over the latest 7 sessions.
The unverified list: the vaccine’s effect size and approval timeline, a direct Twist-Anthropic contract, ST Pharm’s direct mRNA orders, undisclosed royalty rates and option terms. This is why none of these appear in this post as settled facts.

9. Closing summary

Three sentences.

The US biotech rally runs on real structure (M&A, rates, IPOs), but it is past +88.8% in a year with events stacked in Q4. The theme-chasing phase is ending; the event-drawdown-substance selection phase is beginning.
The two August events (the mRNA cancer Phase 3, AI protein design) genuinely redrew the theme map. In particular, the per-patient manufacturing nature of personalized therapy opens a quiet beneficiary path: CDMOs.
In Korea, everything reduces to separating contract-backed substance from theme-borrowed hope. Substance-plus-momentum (Alteogen, HanAll), substance-plus-drawdown (LigaChem, ABL Bio), and the caution list. That distinction is the map this post leaves you.

FAQ

Q. XBI is up +88.8%. Am I too late? A. More precise than “late or not” is “the easy part is over.” Year-one beta (the whole sector rising) has passed; from here, events and stock selection decide returns. That is why discipline comes first: total caps, diversification, tranches.

Q. If US biotech rises, does Korean biotech automatically follow? A. Not automatically. While XBI rose +39%, Korean small/mid biotechs failed to keep up, and flows polarized into large caps only. That gap can be the opportunity, but the gap closes first in names with contract substance. Hence this post’s focus on verifying substance.

Q. Should I buy whenever a licensing headline appears? A. Check the contract type first. A definitive deal (total value, upfront, milestones in the filing) and an evaluation agreement or joint research carry completely different weight. Section 7’s caution list shows exactly those traps.

Q. The mRNA cancer vaccine succeeded. Should I buy related stocks? A. Separate two things. ① It is a Phase 3 success, not an approval, and the absolute effect size is undisclosed. ② No Korean listed company has confirmed direct benefit. ST Pharm’s mRNA manufacturing capability is the closest, but no such order is confirmed. Waiting for full data and order filings beats chasing theme spikes.

Q. What are the data cut-offs? A. US prices are the 8/19 close; Korean quant (RS, flows) is an 8/7 database partially adjusted to 8/19 prices. Events and prices keep moving, so always re-check before trading.

Evidence classification (Appendix)

[Fact]

XBI +88.8% over 1 year, +39.1% YTD; last month biotech +9.7% vs semis −6.0% (8/19 close).
H1 biotech M&A $123B~$134B (varies by tracker), past full-year 2025. Patent-cliff exposure through 2030: $170~300B.
Merck/Moderna intismeran (mRNA-4157) + Keytruda met RFS and DMFS in a 1,137-patient melanoma Phase 3 (8/19). Not an approval; effect size undisclosed. mFLUSIVA FDA approval (8/5).
Anthropic-Claude protein design: 14 of 15 targets, hit rate 22~35% (industry 10~15%), independently verified by Twist and Adaptyv, Twist 8-K and +17%.
Korean contract substance: Alteogen Keytruda SC royalties (Q2 revenue +262%) and $20M Enhertu SC upfront; HanAll IMVT-1402 RA Ph2b ACR20 72.7%; OliX Lilly deal ₩911.7bn; LigaChem J&J $1.7B (option unexercised); ABL GSK ≈₩4tn + Lilly $2.6B; Orum BMS $100M upfront; ST Pharm $56M supply deal; Samsung Bio ₩6.8tn backlog and GSK Rockville purchase.
Flows (20 days, institutions+foreigners): Samsung Bio +₩365bn, Celltrion +₩341.3bn, LigaChem +₩21.2bn, ABL +₩23.6bn. But over the latest 7 sessions LigaChem/ABL saw institutional net selling and foreign net buying.

[Inference]

The semis-to-biotech rotation is measurably under way, with the patent cliff as the structural driver of the M&A supercycle.
AI drug-discovery value is migrating from ‘AI biotechs’ to frontier labs plus verification/synthesis infrastructure (picks and shovels).
Given per-patient manufacturing, approval of personalized mRNA therapy would structurally lift mRNA CDMO demand.
The gap left by Korean small/mid biotechs lagging the US rally likely closes first in names with contract substance.

[Speculation]

ST Pharm winning personalized-mRNA-related orders (capability confirmed, orders not).
LigaChem’s J&J option exercise, FutureChem signing a license, a VKTX takeover scenario.
A formal Twist-Anthropic commercial collaboration emerging.

[Blocked]

INTerpath-001 effect size, OS data, and approval timeline.
Undisclosed terms such as Alteogen’s royalty rate and LigaChem’s final option terms.
Details of Peptron’s evaluation agreement; the fate of D&D Pharmatech’s follow-on program.
The gap between M&A tallies ($123B vs $134B) across trackers.

Method: 108 public sources (filings, STAT, NEJM, CNBC, FierceBiotech, BioSpectator and others) cross-checked against a quantitative screen of 312 Korean listed biotechs (RS and flows), as of 2026-08-20. Source grades S1 (filings) through S4 (blogs, not adopted) were applied, and unverified items are flagged in the text and under [Blocked].

이 글은 리서치·정보 제공용이며 투자 조언이 아닙니다. 종목명은 분석을 위한 예시이며, 매수·매도 권유가 아닙니다. 데이터 기준일: 2026년 8월 20일 KST.

Disclaimer: For research and information purposes only. Not investment advice. Company names are cited for analytical illustration. US prices are as of the Aug 19, 2026 close; Korean quantitative data (RS/flows) are from an Aug 7 database partially adjusted to Aug 19; financial and deal figures are based on company filings and media reports. Clinical and regulatory events are high-risk binary catalysts. Conflict-of-interest note: this post was written with the assistance of Anthropic’s Claude; items involving Anthropic are presented alongside external verification and skeptical views. Data as of August 20, 2026 (KST).

AI Drug Discovery on Korea Invest Insights

A Map of Biotech Investing: Where You Earn Only If the Drug Works, and Where You Earn Whichever Drug Works

TL;DR

1. What Disease Classification Misses: Overlaying Four Axes

2. A Map of Fourteen Sub-Themes

3. The Internal Structure of Personalized Oncology: Economics Differ at Every Stage

4. Results on the Recurring Revenue Axis: Good Structure, Expensive Price

5. The Therapeutics Axis: What the Phase 3 Trial Proved, and What It Has Not

6. The Price Problem for Validated Platforms: ADCs, Bispecifics, and Radiopharmaceuticals

7. The Axis That Still Needs Proof, Yet Has Risen the Most

8. Overall Priority Ranking and the Barbell

Related posts

What's Happening in US Biotech? A Beginner's Map of 8 Big Trends and Their Korean Connections (2026-08-20)

TL;DR (3 lines)

Before we start: the 6 words this post keeps using

1. The big picture: money is moving from semis to biotech

2. The rally’s three engines: why biotech, why now

The patent cliff: the real reason behind the M&A supercycle

3. Two days in August that changed the map

Event ① The first-ever Phase 3 win for an mRNA cancer therapy (8/19)

Event ② An AI designed proteins, and outside labs verified it (8/18)

4. The 8 US themes at a glance

One step deeper into each theme

5. US names to watch: priorities, and the discipline behind them

6. The Korea linkage map: where does this wave land?

Company by company: what is substance and what is hope

One chart: the substance × momentum quadrant

7. The caution list: names that borrowed the theme without the substance

8. The Q4 event calendar and the risks

The honest risk list (red team)

9. Closing summary

FAQ

Evidence classification (Appendix)

[Fact]

[Inference]

[Speculation]

[Blocked]